| Online-Ressource |
Verfasst von: | Goldschmidt, Hartmut [VerfasserIn]  |
| Hegenbart, Ute [VerfasserIn]  |
| Wallmeier, M. [VerfasserIn]  |
| Hohaus, Stefan [VerfasserIn]  |
| Haas, Rainer [VerfasserIn]  |
Titel: | Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma |
Verf.angabe: | H. Goldschmidt, U. Hegenbart, M. Wallmeier, S. Hohaus and R. Haas |
E-Jahr: | 1997 |
Jahr: | September 1997 |
Umfang: | 20 S. |
Fussnoten: | Elektronische Reproduktion der Druck-Ausgabe 29. Oktober 2003 ; Gesehen am 24.04.2025 |
Titel Quelle: | Enthalten in: British journal of haematology |
Ort Quelle: | Oxford [u.a.] : Wiley-Blackwell, 1955 |
Jahr Quelle: | 1997 |
Band/Heft Quelle: | 98(1997), 3, Seite 736-755 |
ISSN Quelle: | 1365-2141 |
Abstract: | We treated 103 multiple myeloma (MM) patients with 7 g/m2 cyclophosphamide (Cy) followed by 300 μg G-CSF/d to harvest peripheral blood progenitor cells (PBPC). PBPC autografts containing > 2.0 × 106 CD34+ cells per kg body weight were obtained at the first attempt from 90/100 evaluable patients. The most significant factor predicting impairment of PBPC collection was the duration of previous melphalan treatment (P < 0.0001). In multivariate discriminate analysis, treatment with melphalan during the most recent chemotherapy cycles prior to mobilization (P = 0.0727) and previous radiotherapy (P = 0.0628) had a marginally significant negative influence on the efficacy of PBPC collection. We found no reduced functional capacity of CD34+ cells to restore haemopoiesis after myeloablative treatment related to the duration of melphalan exposure. At the time of best response to conventional treatment, a median paraprotein reduction of 21% was achieved following high-dose cyclophosphamide (HD-Cy). Two heavily pretreated patients died and one patient developed pulmonary toxicity W.H.O. grade IV following HD-Cy. Potential transplant candidates should undergo mobilization and harvesting of PBPC before melphalan-containing treatment. Combinations of haemopoietic growth factors and their dose modifications should be investigated to improve PBPC collection, to allow a dosage reduction of the mobilization chemotherapy. |
DOI: | doi:10.1046/j.1365-2141.1997.2783095.x |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1046/j.1365-2141.1997.2783095.x |
| Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2141.1997.2783095.x |
| DOI: https://doi.org/10.1046/j.1365-2141.1997.2783095.x |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | G-CSF |
| high-dose cyclophosphamide |
| multiple myeloma |
| peripheral blood progenitor cell mobilization |
| transplantation |
K10plus-PPN: | 1923583824 |
Verknüpfungen: | → Zeitschrift |
Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma / Goldschmidt, Hartmut [VerfasserIn]; September 1997 (Online-Ressource)